{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-329570","form_type":"8-K","ticker":"DSGN","cik":"0001807120","company_name":"Design Therapeutics, Inc.","filed_at":"2026-08-03T12:03:40+00:00","discovered_at":"2026-08-03T12:05:00.257582+00:00","generated_at":"2026-08-03T12:05:04.666568+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Design Therapeutics reports Q2 net loss of $20.2M; modifies RESTORE-FA trial, delays FECD data","bullets":["Net loss of $20.2M for Q2 2026; cash and securities of $207.4M at quarter-end.","RESTORE-FA trial modified: 12-week cohort at 1 mpk, primary endpoint endogenous FXN protein change; data expected Q1 2027.","Phase 1 MAD trial of DT-818 in DM1 initiated; data expected in 2027.","Phase 2 FECD trial of DT-168 delayed to 2027 due to supply issue with eye droppers.","Registrational plan update expected Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-329570","json":"https://secwatch.observer/filing/0001193125-26-329570.json","markdown":"https://secwatch.observer/filing/0001193125-26-329570.md","text":"https://secwatch.observer/filing/0001193125-26-329570.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807120/000119312526329570/0001193125-26-329570-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807120/000119312526329570/dsgn-20260803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-03T12:05:04.666568+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}